Geoff Lindeman

@PTarantinoMD @CCR_AACR PFS in fulvestrant mono arm actually <2 mo. Interesting trend (albeit non-significant) favoring venetoclax for BCL2 strong (IHC 3+) tumors. Findings also suggest BCLXL may be important in post-CDK4/6i setting.

Presented at #ASCO21, results from #VERONICA are now published on @CCR_AACR. No benefit from the addition of venetoclax to fulvestrant in pretreated HR+ MBC. On a side note, fulvestrant monotherapy confirms its poor performance after CDK4/6i (PFS <3 mo.) aacrjournals.org/clincancerres/…

A new paper from WEHI’s breast cancer and bioinformatics researchers has used single-cell transcriptomics to create an extensive ‘atlas’ of how mammary epithelial cells develop. Read the paper in @BCRJournal: …ast-cancer-research.biomedcentral.com/articles/10.11…